- Home
- XGN vs AARD Comparison
XGN vs AARD Comparison
Compare XGN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- AARD
- Stock Information
- Founded
- XGN 2002
- AARD 2017
- Country
- XGN United States
- AARD United States
- Employees
- XGN N/A
- AARD N/A
- Industry
- XGN Medical Specialities
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- AARD Health Care
- Exchange
- XGN Nasdaq
- AARD Nasdaq
- Market Cap
- XGN 138.3M
- AARD 154.9M
- IPO Year
- XGN 2019
- AARD 2025
- Fundamental
- Price
- XGN $7.23
- AARD $11.13
- Analyst Decision
- XGN Strong Buy
- AARD Strong Buy
- Analyst Count
- XGN 2
- AARD 4
- Target Price
- XGN $7.50
- AARD $31.25
- AVG Volume (30 Days)
- XGN 236.6K
- AARD 31.4K
- Earning Date
- XGN 08-04-2025
- AARD 08-14-2025
- Dividend Yield
- XGN N/A
- AARD N/A
- EPS Growth
- XGN N/A
- AARD N/A
- EPS
- XGN N/A
- AARD N/A
- Revenue
- XGN $56,724,000.00
- AARD N/A
- Revenue This Year
- XGN $19.39
- AARD N/A
- Revenue Next Year
- XGN $13.27
- AARD N/A
- P/E Ratio
- XGN N/A
- AARD N/A
- Revenue Growth
- XGN 1.78
- AARD N/A
- 52 Week Low
- XGN $1.71
- AARD $4.88
- 52 Week High
- XGN $7.95
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- XGN 56.74
- AARD N/A
- Support Level
- XGN $7.10
- AARD N/A
- Resistance Level
- XGN $7.95
- AARD N/A
- Average True Range (ATR)
- XGN 0.51
- AARD 0.00
- MACD
- XGN -0.04
- AARD 0.00
- Stochastic Oscillator
- XGN 46.67
- AARD 0.00
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.